These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11812056)

  • 1. GP IIb/IIIa inhibition in primary stenting: 'do it early, make it easy'.
    Montalescot G
    Eur Heart J; 2002 Feb; 23(4):259-60. PubMed ID: 11812056
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of angioplasty with stenting in acute myocardial infarction.
    Herrmann HC
    N Engl J Med; 2002 Aug; 347(5):367-8; author reply 367-8. PubMed ID: 12151478
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet GP IIb/IIIa inhibition in myocardial infarction treated by coronary stenting: ready for prime time.
    Anderson HV
    J Invasive Cardiol; 2000 Mar; 12(3):140-1. PubMed ID: 10877555
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
    N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
    N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving microvascular perfusion with platelet glycoprotein IIb/IIIa receptor inhibition.
    Dippel EJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():12E-16E; quiz 17E. PubMed ID: 12668858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In the era of stabilize and seal, is there a role for GP IIb/IIIa agents in PCI?
    Gilchrist IC
    Catheter Cardiovasc Interv; 2010 May; 75(6):903-4. PubMed ID: 20432396
    [No Abstract]   [Full Text] [Related]  

  • 8. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies].
    Internist (Berl); 1998 Dec; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692
    [No Abstract]   [Full Text] [Related]  

  • 9. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revascularization techniques in acute myocardial infarction.
    Gorman RC; Gorman JH
    N Engl J Med; 2000 Dec; 343(24):1815. PubMed ID: 11185605
    [No Abstract]   [Full Text] [Related]  

  • 11. [Impact of GP IIb/IIIa antagonists in interventional cardiology].
    Scheller B; Hennen B; Böhm M; Nickenig G
    Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800
    [No Abstract]   [Full Text] [Related]  

  • 12. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa antagonists: an attractive new approach to reperfusion in acute myocardial infarction.
    Gambhir DS
    Indian Heart J; 1999; 51(3):259-60, 309. PubMed ID: 10624062
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function.
    Kereiakes DJ
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S3-11. PubMed ID: 17224889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 16. [Glycoprotein IIb/IIIa blockers. Their usefulness in current cardiovascular therapeutics].
    López Cuéllar J
    Arch Inst Cardiol Mex; 1999; 69(3):272-81. PubMed ID: 10529862
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
    De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M
    J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158
    [No Abstract]   [Full Text] [Related]  

  • 18. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?
    Cole JH; Weintraub WS
    Circulation; 2003 Dec; 108(23):2831-3. PubMed ID: 14662689
    [No Abstract]   [Full Text] [Related]  

  • 19. The TARGET trial: hit or miss?
    Moliterno DJ; Topol EJ
    Eur Heart J; 2002 Jun; 23(11):835-7. PubMed ID: 12042001
    [No Abstract]   [Full Text] [Related]  

  • 20. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.